Pengaruh Ekstrak Etanol Momordica Charantia terhadap Sensitivitas Insulin pada Tikus Model Diabetes Mellitus Tipe 2
Abstract
Diabetes mellitus adalah gangguan metabolisme yang ditandai dengan peningkatan kadar gula darah yang disebabkan oleh kekurangan produksi insulin, kerja insulin, atau keduanya. Hiperglikemia kronis diabetes terkait dengan kerusakan jangka panjang, kerusakan, dan kegagalan organ, terutama pada ginjal, mata, jantung, saraf, dan pembuluh darah. Momordica charantia umumnya digunakan sebagai obat herbal untuk diabetes tipe 2 di Asia, Amerika Selatan, dan Afrika Timur. Momordica charantia mengandung charantin, lektin, dan insulin polipeptida-P, yang dapat membantu menyembuhkan diabetes dengan menurunkan kadar glukosa darah. Penelitian ini bertujuan untuk mengetahui dan menganalisis pengaruh dosis ekstrak etanol Momordica charantia terhadap sensitivitas insulin tikus model diabetes mellitus tipe 2. Penelitian ini menggunakan desain penelitian eksperimental, dengan menggunakan metode postest control group design artinya data yang diambil hanya satu kali. Sebanyak 36 ekor tikus digunakan sebagai subjek yang dibagi menjadi 6 kelompok uji. Setiap kelompok mendapatkan perlakuan yang berbeda termasuk pemberian dosis ekstrak etanol Momordica charantia yang berbeda. Pengujian hipotesis dilakukan dengan menggunakan uji anova. Data yang dihasilkan dari ekstrak etanol Momordica charantia dapat dinyatakan bahwa terdapat perbedaan sensitivitas insulin meskipun tidak signifikan secara statistik.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Liu Z, Gong J, Huang W, Lu F, Dong H. The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review. Evidence-based Complement Altern Med. 2021;2021.
Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The Growing Epidemic of Diabetes Mellitus. Curr Vasc Pharmacol. 2019;18(2):104–9.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract [Internet]. 2017;128:40–50. Available from: http://dx.doi.org/10.1016/j.diabres.2017.03.024
Dwiputri AW, Pristianty L, Hermansyah A. Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: A narrative review. J Basic Clin Physiol Pharmacol. 2019;30(6):1–15.
Kurnia AD, Masruroh NL, Melizza N, Prasetyo YB, Hidayani HN. Factors Associated with Dietary Behaviour among Patients with Type 2 Diabetes Mellitus in Rural Indonesia. J ASEAN Fed Endocr Soc. 2022;37(2):1–5.
Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, et al. Clinical Practice Guidelines: Definition, Classification and Diagnosis of Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2019;127(1):S1–7.
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–90.
Rhee EJ. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? Endocrinol Metab. 2022;12(3):415–29.
Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB, et al. A Unified Pathophysiological Construct of Diabetes and its Complications. Trends Endocrinol Metab. 2017;28(9):645–55.
Tran N, Pham B, Le L. Bioactive Compounds in Anti-Diabetic Plants : Biology (Basel). 2020;9(252):1–31.
Song Y, Yang H, Kim J, Lee Y, Kim SH, Do IG, et al. Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy. Mol Metab. 2023;78(September).
Zhou X, Shi H, Zhu S, Wang H, Sun S. Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis. J Diabetes Investig. 2022;13(3):468–77.
Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F, et al. Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats. Arch Med Sci. 2021;17(5):1378–87.
Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020;11(April):1–13.
Yamasaki S, Kadowaki M, Jiromaru T, Takase K, Iwasaki H. Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan. Diabetes Ther [Internet]. 2019;10(3):1139–43. Available from: https://doi.org/10.1007/s13300-019-0609-3
Zhou S, Allard PM, Wolfrum C, Ke C, Tang C, Ye Y, et al. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine. Metabolomics [Internet]. 2019;15(8):1–12. Available from: https://doi.org/10.1007/s11306-019-1565-7
Xu B, Li Z, Zeng T, Zhan J, Wang S, Ho CT, et al. Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents. Molecules. 2022;27(7):1–17.
Peter EL, Kasali FM, Deyno S, Mtewa A, Nagendrappa PB, Tolo CU, et al. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. J Ethnopharmacol [Internet]. 2019;231:311–24. Available from: https://doi.org/10.1016/j.jep.2018.10.033
Cortez-Navarrete M, Pérez-Rubio KG, Escobedo-Gutiérrez M de J. Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review. Pharmaceuticals. 2023;16(4).
Abbas, S.A.N., Raza, S.T., Mir, S.S., Siddiqi, Z., Zaidi, A., Zaidi, Z. and Mahdi, F. (2019), “Association of variants rs7903146 and rs290487 of TCF7L2 gene with diabetic nephropathy and co-morbidities (hypertension and dyslipidemia) in type 2 diabetes mellitus”, Meta Gene, Vol. 20, p. 100561, doi: 10.1016/j.mgene.2019.100561.
Ghasemi, A., Khalifi, S. and Jedi, S. (2014), “Streptozotocin-nicotinamide-induced rat 55 model of type 2 diabetes (review)”, Acta Physiologica Hungarica, Vol. 101 No. 4, pp. 408–420, doi: 10.1556/APhysiol.101.2014.4.2.
Bagchi, D. (2018), “Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome - 2nd Edition”, Acta Endocrinologica (Bucharest), Vol. 14 No. 3, pp. 438– 438, doi: 10.4183/aeb.2018.438.
Vangoori Y, Mishra SS, others. Anti diabetic effect of Momordica charantia (Bitter melone) on Alloxan induced diabetic rabbits. Int J Med Res Health Sci. 2013;2(2):137–42.
DOI: https://doi.org/10.30596/jih.v5i2.20589
Refbacks
- There are currently no refbacks.
Fakultas Kedokteran
Universitas Muhammadiyah Sumatera Utara
Jln.Gedung Arca No. 53 Medan 20217
Telp/HP/Whatsapp: +62 8112570085, +62 857-6248-0974
Website : http://jurnal.umsu.ac.id/index.php/JIH/index
Email : implementahusada@umsu.ac.id